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While sepsis is a leading cause of acute kidney injury in
critically ill patients, the relationship between immune
response and acute kidney injury in less severely ill patients
with infection is not known. Here we studied the
epidemiology, 1-year mortality, and immune response
associated with acute kidney injury in 1836 hospitalized
patients with community-acquired severe and non-severe
pneumonia. Acute kidney injury developed in 631 patients
of whom 329 had severe and 302 had non-severe sepsis.
Depending on the subgroup classification, 16–25% of the
patients with non-severe pneumonia also developed acute
kidney injury. In general, patients with acute kidney injury
were older, had more comorbidity, and had higher biomarker
concentrations (interleukin-6, tumor necrosis factor, D-dimer)
even among patients without severe sepsis. The risk of death
associated with acute kidney injury varied when assessed by
Gray’s survival model and after adjusting for differences in
age, gender, ethnicity, and comorbidity. This risk was
significantly higher immediately after hospitalization but
gradually fell over time in the overall cohort and in those
with non-severe pneumonia. A significantly higher risk of
death (hazard ratio 1.29) was also present in those never
admitted to an intensive care unit. Hence acute kidney injury
is common even among patients with non-severe pneumonia
and is associated with higher immune response and an
increased risk of death.
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Sepsis, an immune response to infection, is a leading cause of
acute kidney injury (AKI) in severely ill patients,1–3 and
development of AKI is associated with increased risk of
death.2,4 Although several studies reported outcome of
sepsis-induced AKI in critically ill patients,1,2,4–8 less atten-
tion has been paid to infected patients with AKI who are less
severely ill. For instance, community-acquired pneumonia
(CAP) is a common, infectious cause of hospitalization in
developed countries.9 Most patients with CAP are not
severely ill and are often treated in non-intensive care
settings. However, the epidemiology and outcome of AKI in
patients with non-severe CAP is unknown. Furthermore,
patients with CAP who develop milder forms of AKI will not
meet existing criteria for severe sepsis (i.e., sepsis with
coexisting severe acute organ dysfunction),10 and are there-
fore unlikely to be enrolled in therapeutic trials of sepsis.11–13
If AKI is associated with increased risk of death in patients
with non-severe CAP and in those without severe sepsis, then
early recognition and treatment could improve outcome
from AKI.
Inflammation is thought to have a causal role in sepsis-
induced AKI in animals,14–16 but data in humans are
inconclusive. Several authors found increased concentrations
of inflammatory, coagulation, and fibrinolysis markers in
critically ill patients with AKI.17–19 However, an important
limitation of these studies is that it is unclear whether
immune markers were associated with AKI itself, or
coexisting severe organ dysfunction (severe sepsis) that may
have contributed to increased immune response.20,21 Under-
standing immune response associated with AKI in patients
without severe sepsis is essential for development of immune
modulating therapies for AKI.
Using Risk, Injury, and Failure (RIFLE) criteria to classify
AKI in a large multicenter cohort of patients hospitalized
with CAP, the goals of this prospective observational study
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were threefold. First, to describe differences in baseline
characteristics and outcomes between hospitalized CAP
patients with and without AKI. Second, to examine the risk
of AKI in patients with milder forms of CAP and whether
development of AKI in an otherwise non-severe pneumonia
is associated with adverse outcomes. We used the Pneumonia
Severity Index classes I–III,22 confusion, uremia, respiratory
rate, low blood pressure, age 65 years or older (CURB-65)
group 1,23 those who never developed severe sepsis,24 and
those who were never admitted to intensive care unit, as
proxies for non-severe CAP. Third, to examine immune,
coagulation, and fibrinolysis pathways among patients
with and without AKI, in those who do and do not develop
severe sepsis.
RESULTS
Baseline characteristics of study participants
Of the 2320 patients enrolled in the study, 291 were excluded
because they were discharged from the emergency depart-
ment, and another 134 patients were excluded because the
clinical team ruled out CAP during the first 3 days of
hospitalization. Of the remaining 1895 patients with CAP, we
excluded patients who were either receiving dialysis or had
history of end-stage renal disease (n¼ 48), and in whom
serum creatinine was never obtained (n¼ 11). Of the 1836
patients who formed the study cohort (Figure 1), premorbid
baseline creatinine was estimated in 1745 patients using the
recommended Modification of Diet in Renal Disease
equation.
Of the 631 patients (34%) who met criteria for AKI, 307
(49%), 135 (21%), and 189 (30%) reached maximum RIFLE
stages, respectively, during hospitalization. Of the 91 patients
with known premorbid baseline creatinine, we found
moderate agreement between premorbid creatinine and the
estimated creatinine to classify patients with AKI (Cohen’s k
coefficient¼ 0.70, 95% CI 0.52–0.87, Po0.0001). Nearly two-
thirds of patients developing AKI had already done so at
hospital admission (n¼ 399, 63.2% of patients with AKI).
Table 1 shows the demographic characteristics and severity of
illness on day 1 of hospital admission stratified by AKI, and
by severity of AKI. Patients with AKI were predominantly
older, of white race, had more preexisting comorbidity, and
had more severe CAP.
Hospital course and outcome for patients with and
without AKI
Table 2 shows hospital course and outcomes for patients with
and without AKI. One-third (31.1%, n¼ 572) of CAP
patients developed severe sepsis (i.e., had a Sequential Organ
Failure Assessment (SOFA) score10 of X3 in at least one
organ system during the entire hospitalization), of which
more than one-half (57.5%) developed AKI (n¼ 329).
Although overall intensive care use was only 16%, more
than a third of patients with AKI (39%) were admitted to the
intensive care unit at some point during hospitalization, of
which 18% received mechanical ventilation. Patients with
AKI, on an average, incurred higher median hospital length
of stay compared to patients without AKI (8 vs 5 days,
Po0.001).
Patients with AKI had a higher risk of death at each
time point, such as by hospital discharge (11 vs 1.3%,
Po0.001), by 90 days (24 vs. 9.8%, Po0.001), and by 1 year
(36.3 vs 20.1%, Po0.001; Table 2). Mortality increased with
increased severity of AKI and was 29.6, 40.7, and 43.9% for
maximum stages RIFLE, respectively, at 1 year (Po0.001;
Figure 2a).
Using Gray’s survival model, we found that the hazard
ratios for association between AKI and risk of death varied
significantly over 365 days after hospitalization for CAP. The
unadjusted hazard ratios were highest during the first 100
days after presentation, subsequently decreased, but never-
theless persisted over the entire 1 year of follow-up (hazard
ratio range 1.45–2.79, Po0.001; Table 4). When adjusted for
differences in age, gender, race, and the Charlson Comor-
bidity Index the hazard ratios were attenuated (adjusted
hazard ratio range 1.10–2.10, Po0.001; Table 4), but
nevertheless remained significant up to 100 days after CAP
(Figure 3a).
Similar risk of death was present when absolute (adjusted
hazard ratio 1.12, 95% CI 1.04–1.20, P¼ 0.001), relative
(adjusted hazard ratio 1.12, 95% CI 1.04–1.19, P¼ 0.002), as
well as ratio (adjusted hazard ratio 1.10, 95% CI 1.04–1.17,
P¼ 0.001) of change in glomerular filtration rate were used
in the model instead of AKI. We also found that the
mortality rates were not different between patients who
presented with AKI at hospital admission and those who
developed AKI during hospitalization. Similarly, there was
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Figure 1 | Subject disposition for the Genetic and
Inflammatory Markers of Sepsis study cohort. AKI, acute
kidney injury
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no difference in mortality associated with AKI among
those with and without chronic kidney disease (data not
shown).
Risk of AKI, hospital course, and outcome in non-severe CAP
Not surprisingly, the risk of AKI was lower in patients with
non-severe CAP. Of the 1030 patients within Pneumonia
Severity Index classes I–III, 20.3% of patients (n¼ 209)
developed AKI. Of the 806 patients within CURB-65 group 1,
16.4% of patients (n¼ 132) developed AKI. Of patients who
never developed severe sepsis (n¼ 1264) and those never
admitted to the intensive care unit (n¼ 1544), the risk of AKI
was 23.8% (n¼ 302) and 25% (n¼ 386). Patients with AKI
within Pneumonia Severity Index classes I–III and CURB-65
group 1 were more likely to develop severe sepsis, be
admitted to intensive care unit, and be mechanically
ventilated (Po0.001; Table 3).
Non-severe CAP patients with AKI incurred higher
length of hospital stay, in-hospital and 90-day mortality
(Table 3). At 1 year, mortality varied from 17.2 to 34.2% for
patients with AKI within the four non-severe CAP subgroups
Table 1 | Baseline characteristics of patients with AKI following CAP
No. (%)
Characteristic AKIa (n=631) No AKI (n=1205) P-value Riskb (n=307) Injuryb (n=135) Failureb (n=189) P-value
Age, mean (s.d.), years 73.4 (14.5) 65.2 (17.1) o0.001 74.2 (14) 76.4 (13) 70 (15.4) o0.001
Male gender 320 (51) 634 (53) 0.43 153 (24) 63 (10) 103 (16) 0.303
White race 542 (85) 951 (79) 0.003 273 (43) 114 (18) 155 (24) 0.085
Baseline creatinine 0.93 (0.3) 0.89 (0.2) o0.001 0.9 (0.1) 0.9 (0.1) 0.9 (0.5) 0.042
Charlson Comorbidity Indexc
Mean (s.d.) 2.1 (2.2) 1.7 (2.1) o0.001 2.1 (2.2) 2.2 (2.1) 1.8 (2.0) 0.109
Index 40 491 (77.8) 831 (68.9) 0.0001 239 (77.8) 111 (82.2) 141 (74.6) 0.266
Chronic kidney disease 24 (3.8) 9 (0.7) o0.001 5 (1.6) 9 (6.6) 10 (5.3) 0.017
Cardiac disease 207 (38.2) 260 (24.1) o0.001 111 (53.6) 49 (23.7) 47 (22.7) 0.116
Lung disease 225 (36) 478 (40) 0.093 117 (52) 49 (21.8) 59 (26.2) 0.293
Diabetes 151 (23.9) 210 (17.4) 0.001 69 (22.5) 42 (31.1) 40 (21.1) 0.083
Prior antibiotic use 101 (16) 222 (18.4) 0.20 52 (17) 18 (13.3) 31 (16.4) 0.541
Pneumonia severity index, mean (s.d.)d 105.5 (31.4) 78.5 (28.5) o0.001 116.5 (37.6) 126.8 (34.5) 124.5 (39.4) 0.009
Pneumonia severity index class
I and II 81 (13) 487 (40.4) o0.001 26 (62) 4 (9.5) 12 (28.5) 0.035
III 128 (20.3) 334 (28) 52 (59.1) 17 (19.3) 19 (21.6)
IV 283 (45) 330 (27.3) 134 (48.5) 55 (20) 87 (31.5)
V 139 (22) 54 (4.5) 95 (42.3) 59 (26.2) 71 (31.5)
CURB-65 score, mean (s.d.)e 2.4 (1.0) 1.4 (1.0) o0.001 2.3 (1.07) 2.6 (0.9) 2.3 (1.1) 0.0042
CURB-65 group
I 132 (21) 674 (56) o0.001 73 (23.8) 14 (10.4) 45 (24) 0.013
II 195 (31) 331 (27.4) 92 (30) 43 (32) 60 (31.7)
III 304 (48) 200 (16.6) 142 (46.2) 78 (58) 84 (44.5)
APACHE III score, mean (s.d.)f 47 (15.2) 36.7 (11.8) o0.001 44.8 (14) 47.1 (14) 50.3 (17) o0.001
SOFA score, mean (s.d.)g 3.3 (2.2) 1.8 (1.4) o0.001 2.8 (2) 3.6 (1.9) 4 (2.5) o0.001
Severe sepsis on day 1h 165 (26.1) 102 (8.46) o0.001 59 (19.2) 26 (19.2) 80 (42.3) o0.001
Abbreviations: AKI, acute kidney injury; APACHE, Acute Physiology and Chronic Health Evaluation; CURB-65, confusion, uremia, respiratory rate, low blood pressure, age 65
years or older; s.d., standard deviation; SOFA, Sequential Organ Failure Assessment.
aPatients were classified to have developed AKI if they met any of Risk, Injury, or Failure stages at any time during hospitalization as proposed by the Acute Dialysis Quality
Initiative.30
bFor severity of AKI, patients were classified according to the maximum RIFLE stage (Risk, Injury, or Failure) reached during the entire hospitalization as proposed by the Acute
Dialysis Quality Initiative.30
cAccording to the method of Charlson et al.33
dPneumonia Severity Index was measured according to criteria by Fine et al.22 in the emergency department in 1546 (84.2%) subjects. There were no significant differences
between subjects who did and did not have a Pneumonia Severity Index measured.
eAccording to criteria by Lim et al.23
fAPACHE III score assessed on first hospital day regardless of whether subject was admitted to an intensive care unit or not.34
gSOFA score assessed on the first day of hospital admission according to criteria by Vincent et al.10
hDefined as sepsis plus acute organ dysfunction according to 2001 international consensus criteria for severe sepsis.24
Table 2 | Hospital course and outcomes in patients with and
without AKI in the overall cohort
No. (%)
Characteristica AKI No AKI P-value
Developed severe sepsis 329 (52.1) 243 (20.1) o0.001
Intensive care unit admission 245 (39) 47 (4) o0.001
Mechanical ventilation 116 (18.4) 13 (1) o0.001
Length of hospital stay, median (IQR) 8 (12–5) 5 (7–4) o0.001
Hospital mortality 70 (11.1) 16 (1.3) o0.001
90-day mortality 151 (24) 118 (9.8) o0.001
1-year mortality 229 (36.3) 242 (20.1) o0.001
Abbreviations: AKI, acute kidney injury; IQR, interquartile range.
aHospital course and outcome in the entire cohort of 1836 patients with
community-acquired pneumonia.
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(Figure 2b). Patients admitted to medical wards with AKI
had higher mortality compared to those without AKI (34.2 vs
19.7%, Po0.001). This increased risk of death was not
only seen with more severe AKI. Of patients with stage
Risk (61%), the mortality was higher with AKI (30.1 vs
19.6%, Po0.001) (hazard ratio 1.67, 95% CI 1.28–2.18,
Po0.001).
The unadjusted hazard ratios for 1-year mortality ranged
from 1.03 to 3.65 within the four non-severe CAP subgroups
(Table 4). The hazard ratios remained unchanged when
adjusted for age, gender, race, and the Charlson Comorbidity
Index for those admitted to medical wards with AKI
(adjusted hazard ratio 1.29, 95% CI 1.03–1.60, Po0.023).
Using Gray’s model, we found that the adjusted hazard ratio
for death in patients within CURB-65 group 1 varied over the
1-year follow-up (adjusted hazard ratio range 0.85–2.97,
P¼ 0.001). The risk of death associated with AKI was high
immediately after CAP in patients admitted to hospital
(hazard ratio 2.73, 95% CI 1.52–4.92). Subsequently,
although the hazard ratios declined, the risk of death
associated with AKI nevertheless remained significant up to
50 days (Figure 3b).
Biomarker concentration in patients with and without AKI
Figure 4 shows the plasma biomarker concentrations during
the first week of hospitalization among patients with and
without AKI stratified by severe sepsis. Patients with AKI who
developed severe sepsis had higher concentrations of
interleukin-6, 10, and tumor necrosis factor at presentation
to the emergency department and during the first week of
CAP (Figure 4a). The geometric mean concentration on day
1 for AKI vs no AKI was—interleukin-6: 111.8 vs 42 pg/ml,
Po0.001; interleukin-10: 8.9 vs 6.0 pg/ml, P¼ 0.026; and
tumor necrosis factor: 8.4 vs 4.5 pg/ml, Po0.001. Impor-
tantly, of patients without severe sepsis, similar patterns in
interleukin-6 and tumor necrosis factor concentrations were
noted in patients with and without AKI during the first week
of CAP (Po0.001), although the magnitude of difference was
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Figure 2 |One-year mortality in patients with and without AKI in the overall cohort and within non-severe CAP subgroups. (a) The
Kaplan–Meier failure plots by maximum RIFLE stage for probability of death in the entire CAP cohort, which at 1 year was higher in patients
with AKI than in patients without AKI (log rank Po0.001). (b) Failure plots for probability of death at 1 year within the four non-severe CAP
subgroups. Non-severe CAP patients with AKI in each of the four subgroups had higher probability of death associated with AKI at 1 year
compared to those without AKI (log rank Po0.01 for all subgroups). AKI, acute kidney injury; CAP, community-acquired pneumonia; RIFLE,
Risk, Injury, and Failure criteria.
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only modest. The geometric mean concentration on day 1 in
those without severe sepsis for AKI vs no AKI was—
interleukin-6: 48.6 vs 35 pg/ml, Po0.03; and tumor necrosis
factor: 6.5 vs 4.9 pg/ml, Po0.001.
Significant derangement in coagulation occurred in
patients with AKI (Figure 4b). Of patients who developed
severe sepsis, higher concentration of thrombin–antithrom-
bin complexes (Po0.001) and lower concentration of
antithrombin persisted during the first week of CAP
(Po0.001) in patients with AKI. Day 1 geometric mean
concentration for AKI vs no AKI was 6.3 vs 4.9 mg/ml for
thrombin–antithrombin complexes (P¼ 0.08) and 79.8 vs
88.1 mg/ml, for antithrombin (Po0.001). In contrast, of
patients without severe sepsis, circulating concentrations of
thrombin–antithrombin complexes, factor IX, and antith-
rombin did not differ between those with developing and not
developing AKI (Figure 4b).
Patients with severe sepsis who developed AKI had
marked elevation in D-dimer and plasminogen activator
inhibitor-1 concentrations during the first week of pneumo-
nia (P¼ 0.001; Figure 4c). The geometric mean concentration
on day 1 in AKI vs no AKI was—D-dimer: 901 vs 643 ng/ml,
P¼ 0.019; and plasminogen activator inhibitor1: 7.9 vs
4.0 ng/ml, P¼ 0.001. In contrast, of patients without severe
sepsis, only circulating D-dimer concentration was higher on
day 1 (689.3 vs 494.9 ng/ml, P¼ 0.001) and during the first
week of CAP (Po0.001).
DISCUSSION
We found, perhaps not surprisingly, that AKI was very
common in CAP. Importantly, however, even in those who
appeared to have an uncomplicated course, as defined by
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Figure 3 |Varying risk of death associated with AKI over one
year after CAP hospitalization. Varying hazard ratios with 95%
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following hospitalization for pneumonia (b). AKI, acute kidney
injury; CURB, confusion, uremia, respiratory rate, low blood
pressure, age 65 years or older.
Table 3 | Hospital course and outcomes in patients with and
without AKI in non-severe CAP subgroups
No. (%)
Characteristic AKI No AKI P-value
Pneumonia Severity Index classes I–IIIa (n=209) (n=821)
Developed severe sepsis 82 (39.2) 109 (13.2) o0.001
Intensive care unit admission 74 (35.4) 24 (3) o0.001
Mechanical ventilation 35 (16.7) 5 (0.6) o0.001
Length of hospital stay, median, IQR 7 (5–10) 5 (4–7) o0.001
Hospital mortality 10 (4.8) 3 (0.4) o0.001
90-day mortality 20 (9.6) 40 (4.9) 0.009
1-year mortality 36 (17.2) 89 (10.8) 0.011
CURB-65 group 1b (n=132) (n=674)
Developed severe sepsis 67 (50.8) 96 (14.2) o0.001
Intensive care unit admission 64 (48.5) 20 (3) o0.001
Mechanical ventilation 35 (26.5) 5 (0.7) o0.001
Length of hospital stay, median, IQR 9 (5–15) 5 (4–7) o0.001
Hospital mortality 9 (6.8) 2 (0.3) o0.001
90-day mortality 18 (13.6) 35 (5.2) o0.001
1-year mortality 28 (21.2) 79 (11.7) 0.003
Non-severe sepsis cohortc (n=302) (n=962)
Intensive care unit admission 53 (17.5) 30 (2) o0.001
Length of hospital stay, median, IQR 6 (5–8) 5 (4–7) o0.001
Hospital mortality 3 (0.99) 1 (0.1) 0.016
90-day mortality 36 (11.9) 67 (6.9) 0.006
1-year mortality 75 (24.8) 152 (15.8) o0.001
Non-ICU cohortd (n=386) (n=1158)
Developed severe sepsis 137 (35.5) 216 (18.6) o0.001
Length of hospital stay, median, IQR 6 (4–8) 5 (4–7) o0.001
Hospital mortality 20 (5.1) 14 (1.2) o0.001
90-day mortality 77 (19.9) 108 (9.3) o0.001
1-year mortality 132 (34.2) 228 (19.7) o0.001
Abbreviations: AKI, acute kidney injury; CAP, community-acquired pneumonia;
CURB-65, confusion, uremia, respiratory rate, low blood pressure, age 65 years or
older; IQR, interquartile range.
aHospital course and outcome in the subgroup of 1030 non-severe CAP patients as
defined by Pneumonia Severity Index classes I–III at presentation to the emergency
department according to criteria by Fine et al.22
bHospital course and outcome in the subgroup of 806 non-severe CAP patients as
defined by CURB-65 group 1 at presentation to the emergency department
according to criteria by Lim et al.23
cHospital course and outcome in the subgroup of 1264 non-severe CAP patients as
defined by maximum Sequential Organ Failure Assessment score less than 3 during
entire hospitalization according to criteria by Vincent et al.10
dHospital course and outcome in the subgroup of 1544 patients who were never
admitted to the ICU during the entire hospitalization.
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different criteria, AKI was still very common, developing in
around one-quarter of patients. In this latter group,
development of AKI was associated with considerable
mortality. Within those developing severe sepsis, AKI
occurred in patients who also had evidence of greater
activation of inflammatory, coagulation, and fibrinolysis
pathways. Among the patients with less severe CAP, AKI was
associated with modest but significant differences in immune
and fibrinolysis activation. This study, to the best of our
knowledge, is the first large-scale investigation of the
Table 4 | Hazard ratios for association between AKI and 1-year mortality
Characteristic Hazard ratio for mortality in patients with AKI 95% CI P-value
Unadjusted
Overall cohorta 1.45–2.79 1.12–3.54 o0.001
Pneumonia Severity Index classes I–III 1.66 1.13–2.45 0.01
CURB-65 group 1b 1.03–3.65 0.57–8.94 0.0001
Non-severe sepsis subgroup 1.67 1.26–2.19 0.0003
Non-intensive care unit subgroup 1.94 1.57–2.41 o0.001
Adjustedc
Overall cohorta 1.10–2.10 0.85–2.67 o0.001
Pneumonia Severity Index classes I–III 1.39 0.94–2.05 0.10
CURB-65 group 1b 0.85–2.97 0.47–7.29 0.001
Non-severe sepsis subgroup 1.14 0.86–1.51 0.35
Non-intensive care unit subgroup 1.29 1.03–1.60 0.023
Abbreviations: AKI, acute kidney injury; CI, confidence interval; CURB-65, confusion, uremia, respiratory rate, low blood pressure, age 65 years or older.
a,bHazard ratios for association between AKI and 1-year mortality for overall cohort and for the subgroup CURB-65 group 1 was estimated from Gray’s model39 using nine time
nodes and eight intervals. Range of hazard ratios and 95% CI estimates from the Gray’s model are shown.
cAdjusted for age, gender, race, and Charlson Comorbidity Index.
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Figure 4 |Circulating inflammatory, coagulation, and fibrinolysis marker concentrations in 1380, 712, and 710 patients with and
without acute kidney injury, stratified by severe sepsis during first week of CAP. (a) Inflammatory biomarkers (interleukin
(IL)-6, -10 and tumor necrosis factor (TNF)). (b) Coagulation biomarkers (thrombin–antithrombin complexes, factor IX, and antithrombin
(AT)). (c) Biomarkers of fibrinolysis (D-dimer and plasminogen activator inhibitor-1 (PAI-1)). Geometric mean plasma concentrations of IL-6,
10, TNF, TAT, D-dimer, and PAI-1were significantly increased in patients with AKI who developed severe sepsis (solid line with diamonds)
when compared to patients without AKI (dashed line with triangles), during the first week of pneumonia (Po0.001). In contrast, plasma
antithrombin concentrations were lower in patients with AKI (Po0.001). Of patients without severe sepsis, plasma concentrations of IL-6,
TNF, and D-dimer were significantly higher in patients with AKI (solid line with squares) compared to those without AKI (dashed line with
crosses) (Po0.001). AKI, acute kidney injury; CAP, community-acquired pneumonia.
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epidemiology and outcome of AKI, and immune response to
CAP in patients with AKI. The result of our study suggests
that AKI is common in patients with CAP even among those
without severe sepsis or even severe CAP. Furthermore, the
immune response to infection is different in patients with
and without AKI.
An overall 34% incidence of AKI in patients with CAP is
very similar to that reported for critically ill patients.5 Our
estimate is likely to rise further with increasing prevalence of
chronic kidney disease as the populations in the developed
world and even in parts of the developing world age.
Development of AKI was associated with high risk of death
early on, declining subsequently, yet persisting up to 100 days
after hospitalization for CAP. Our findings are surprising
given that most patients with AKI were discharged by 8 days,
suggesting that the risk of death persists even though the
clinical signs have resolved and subjects appeared to be stable
for discharge after CAP.25
We also found that AKI was associated with a significant
increase in the risk of death even in patients with non-severe
CAP. We chose four different definitions for ‘non-severe’
CAP. Pneumonia Severity Index and CURB-65 are widely
validated severity indices for CAP. We also used absence of
severe sepsis and lack of intensive care use as two additional
methods to identify patients who were less severely ill
throughout hospitalization with pneumonia. Surprisingly, we
found that many patients with non-severe CAP admitted to
medical wards developed AKI and although most had mild
AKI (Risk), there was still an increased risk of death. This
finding is consistent with other studies of AKI showing that
small changes in kidney function are associated with higher
mortality.26–28 Similarly, of the lower severity patients defined
by CURB-65, development of AKI was still associated with
higher mortality. Importantly, these non-severe CAP patients
with AKI would not have met inclusion criteria for any of the
major sepsis clinical trials and yet the presence of AKI was
associated with a significant increase in mortality. We
speculate that this group of patients may be better suited to
the study of novel therapies for AKI because their
comorbidities are fewer and the risk of death attributable
to AKI may be more readily modifiable than that for AKI in
severely ill patients.
As expected, we found higher concentrations of inflam-
matory, coagulation, and fibrinolysis markers in patients with
AKI who developed severe sepsis similar to other studies.17,29
However, a key finding of our study is that patients with AKI
but without severe sepsis also had higher inflammatory and
fibrinolysis markers. These observations suggest that the
immune response in CAP is different in patients with AKI
and may have a bidirectional relationship. Higher immune
response might have caused AKI or might have occurred as a
consequence of AKI (e.g., decreased elimination, increased
cytokine release) or both. Because many of our patients had
AKI on day 1, we were unable to delineate a temporal
association to support any cause–effect relationship between
AKI and immune response.
There are important limitations to our study. First, as is
the case with most studies of AKI, we did not know
premorbid creatinine in many patients and relied on
screening for chronic kidney disease by medical history and
estimated creatinine according to recommended guidelines.30
This might have resulted in an overestimate in the incidence
of AKI if there was a higher than reported underlying
prevalence of chronic kidney disease among our patients.
Nevertheless, we found that there was a moderate con-
cordance between known premorbid creatinine and esti-
mated baseline creatinine in classifying patients with AKI,
suggesting that our results are less likely to be affected by
misclassification bias.31
Second, we were unable to control for fluid, hemody-
namic, and other concurrent interventions that could have
influenced course of AKI, biomarker patterns, and outcomes.
Third, there is no gold standard for the term ‘non-severe
CAP’. We therefore presented results defining non-severe
CAP in four ways. We chose these definitions on the basis of
clinical face validity, but recognize that the definitions are
arbitrary. Fourth, we did not account for the competing risk
between mortality associated with sepsis-induced AKI and
subsequent decline in kidney function, ultimately reflected as
either chronic kidney disease or end-stage renal disease, due
to smaller cohort and shorter duration of follow-up.
Our study also has several strengths. First, being a
multicenter study, our finding of high risk of AKI and its
association with adverse outcomes independent of severity of
CAP is highly generalizable. Second, we showed that the risk of
death associated with AKI persists long after discharge
following CAP hospitalization, though the mechanism
responsible for late death is unclear in patients with AKI.
Third, by considering subjects with CAP alone, we enrolled a
more homogenous group of patients with early sepsis (CAP),
unlike earlier studies that enrolled patients with different
infections and at varying time points. Fourth, we were able to
quantify that most sepsis-induced AKI occurs before hospi-
talization and therefore were able to examine the timing of
AKI. Fifth, we carefully measured biomarkers from the time of
admission when biomarker activation is generally highest and
when concentrations are least likely to be modified by therapy.
We stratified biomarker analysis by severe sepsis to account for
the independent relationship between AKI and biomarkers in
the absence of coexisting organ dysfunction; unlike many
other studies that measured cytokines late and after coexisting
organ dysfunctions were already evident.
In summary, the results of our study show that AKI occurs
in approximately one-third of patients with CAP, and in a
quarter of patients with non-severe CAP. Occurrence of AKI
is associated with higher concentrations of immune and
fibrinolysis markers even in those without severe sepsis, and
an increased risk of death. Our study underscores the
importance of increased awareness of this high incidence of
AKI and mortality after pneumonia, and the need for
development of prevention/treatment strategies especially for
patients with non-severe CAP who have not typically been
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included in sepsis trials. In addition, further research is
needed to understand the mechanism of death after AKI,
particularly as the risk appears to persist long after AKI and
CAP have resolved.
MATERIALS AND METHODS
Study design and selection of participants
The analyses were based on all hospitalized patients enrolled in the
Genetic and Inflammatory Markers of Sepsis (GenIMS) study.32
GenIMS is a large, multicenter, observational cohort study of
subjects with CAP presenting to the emergency departments of 28
teaching and nonteaching hospitals in the United States between
November 2001 and November 2003. Eligible patients were X18
years old and had a clinical and radiological diagnosis of CAP using
criteria by Fine et al.22 Exclusion criteria included transfer from
another hospital, discharge from an acute care hospital within the
previous 10 days, pneumonia within the previous 30 days, chronic
dependency on mechanical ventilation, cystic fibrosis, active
pulmonary tuberculosis, admission for palliative care, prior
enrollment in the study, incarceration, and pregnancy. The
institutional review boards at all participating sites approved the
study, and we obtained written informed consent from all
participants or their proxies.
Methods of data collection
We gathered baseline and sequential clinical information by
structured patient or proxy interviews. We prospectively ascertained
comorbid conditions using the Charlson Comorbidity Index,33 and
severity of illness using the Acute Physiology and Chronic Health
Evaluation III score,34 and Pneumonia Severity Index.22 We
calculated CURB-65 score23 retrospectively with altered mental
status or a new change in Glasgow Coma Scale score as proxy
measures for confusion.35 We defined severe sepsis as infection and
acute organ dysfunction, following international consensus criter-
ia.24 We defined acute organ dysfunction as a new SOFA score of
three or greater in any of six organ systems.10
Definition of acute kidney injury
We classified AKI using the maximum RIFLE stages, as proposed by
the Acute Dialysis Quality Initiative30 at any time during
hospitalization. The RIFLE stage was determined based on the
worse of either serial serum creatinine or urine output. For patients
with no known premorbid creatinine and no known medical history
of chronic kidney disease, we estimated premorbid creatinine using
the Modification of Diet in Renal Disease equation,36 as recom-
mended by the Acute Dialysis Quality Initiative. We then selected
the lower creatinine value from either the hospital admission
creatinine or the Modification of Diet in Renal Disease creatinine as
the baseline value.37 Patients were classified as stage Risk, if serum
creatinine was 1.5 times the baseline creatinine, or urine output
o0.5 ml/kg/h for 6 h; stage Injury, if serum creatinine was twice the
baseline, or urine output o0.5 ml/kg/h for 12 h; stage Failure, if
serum creatinine was thrice the baseline, or creatinine X4 mg/dl
with an acute rise 40.5 mg/dl, or urine output o0.3 ml/kg/h for
24 h, or anuria for 12 h.30
Criteria for non-severe CAP
We used four different sets of criteria to classify the severity of
CAP.22–24,38 We defined non-severe CAP as classes I–III for
Pneumonia Severity Index calculated at admission and group 1
for CURB-65 to identify patients who had non-severe CAP at
hospital admission. We also chose patients who did not develop
severe sepsis according to the SOFA score of less than three in any of
six organ systems, and those never admitted to the intensive care
unit to identify patients who were less severely ill with CAP
throughout index hospitalization.
Outcome variables
Our primary outcome was 1-year all-cause mortality. Secondary
outcomes included length of stay, in-hospital and 90-day mortality.
Study coordinators ascertained deaths in hospital and post-
discharge mortality was ascertained by telephone and National
Death Index search.
Laboratory procedures
Blood was drawn for cytokines (tumor necrosis factor, interleukin-
6, -10), coagulation (thrombin–antithrombin complexes, antithrombin,
factor IX), and fibrinolysis (plasminogen activator inhibitor-1, and D-
dimer) markers in the emergency department and daily for the first
week, while a subject remained in hospital. Detailed sample handling
and laboratory procedures have been described elsewhere.32 We
rechecked all outlier values and masked laboratory personnel to clinical
data. Although we analyzed inflammatory markers in 1380 patients, for
logistical and cost reasons, coagulation and fibrinolysis markers were
assessed only in a random subset of 712 and 710 patients.
Statistical analysis
We conducted univariate comparisons using w2-tests, Student’s
t-tests, or their nonparametric equivalents, as appropriate. We
assessed 1-year mortality by comparing Kaplan–Meier failure plots
using log-rank test. We conducted survival analyses using Cox
proportional hazard model to estimate hazard ratios for association
between AKI and 1-year mortality. We used Gray’s model to
estimate hazard ratios for nine time nodes and eight intervals, if
hazards failed Cox’s proportionality assumption.39 We adjusted for
potential confounders by expanding the models to include age, sex,
race/ethnicity, and the Charlson Comorbidity Index.
We present sequential biomarker data as plots of daily means
stratified by development of AKI and severe sepsis. We assumed a
log-normal distribution of biomarkers and analyzed data in natural
log scale. We constructed Tobit models to account for truncated data
that fell below detection thresholds,40 and generated daily geometric
means to compare the concentration between groups for a single
time point. For sequential data, we conducted regression analysis
with mixed models that accounted for correlation of repeated
measures over time,41 incorporating Tobit models as necessary.42
Models included linear and quadratic terms to allow evaluation of
trends. All analyses were performed using SAS 9.0 (SAS Institute,
Cary, NC, USA) assuming statistical significance at Po0.05.
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